Agios Pharmaceuticals, Inc. (AGIO)

Over the past six months, Agios reported its Third Quarter 2025 financial results, including $12.9 million in PYRUKYND net revenues, and announced a PDUFA goal date of December 7, 2025, for PYRUKYND's U.S. sNDA in thalassemia. AQVESME™ (mitapivat) received FDA approval on December 24, 2025. Agios released its Q4 and Full Year 2025 financial results on February 12, 2026. PYRUKYND® (mitapivat) was approved for adults with thalassemia in the United Arab Emirates on March 2, 2026. Agios announced it was advancing mitapivat toward potential U.S. accelerated approval in sickle cell disease following a positive pre-sNDA meeting with the FDA, leading to a significant stock increase. Year-to-date, AGIO stock has increased by 20.9%. There has been insider selling activity in March 2026 and September 2025.

Specific demand seasonality for Agios Pharmaceuticals, Inc.'s products and services is not explicitly detailed in the provided information.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel therapies for rare genetic diseases, particularly in classical hematology. The company utilizes genomic discovery, metabolic profiling, and precision medicine to advance small-molecule candidates that address metabolic dysfunction. Key products and pipeline candidates include PYRUKYND (mitapivat), approved for hemolytic anemias in adults with PK deficiency and being evaluated for thalassemia and sickle cell disease; Tebapivat, a PK activator in development for lower-risk MDS-associated anemia and sickle cell disease; AG-181, a PAH stabilizer for phenylketonuria (PKU); AG-236, an siRNA targeting TMPRSS6 for polycythemia vera; and AG-946, a novel PK activator in preclinical development.

Agios Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts, United States. The company markets its therapies directly in the United States and collaborates with global pharmaceutical companies for commercialization in Europe and other regions. PYRUKYND has received approval in Saudi Arabia and the United Arab Emirates for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.

Agios Pharmaceuticals maintains a positive brand reputation, emphasizing its patient-centric approach and collaborative efforts. The company is committed to understanding and addressing the needs of patients with rare diseases, fostering strong bonds with patient communities, partners, and colleagues. MarketBeat has given Agios Pharmaceuticals a news sentiment score of 0.49, and the company has seen increased news coverage, with 19 articles tracked in a recent week compared to an average of 7.

Agios Pharmaceuticals, Inc. has significant institutional ownership, with 90.72% held by institutions and 1.15% by individuals. As of April 7, 2026, 243 institutional owners and shareholders held a total of 60,100,143 shares. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., Farallon Capital Management Llc, and State Street Corp. Notable individual insider owners include Celgene European Investment Co LLC and Robert Nelsen.